bbhuey: Good question. FDA policy disallows official FDA publication of pending 510(k) applications. Not only that, only SE approvals are published; NSEs (i.e., disapprovals) are not revealed. However, it's likely CSMG would have notified shareholders of additional FDA filing(s) as happened pursuant to LTC's first 510(k).
These are my opinions and sentiments only. Take them for what they're worth. Do your DD. Buying stocks is risky!
"If we could sell our experiences for what they cost us, we'd all be millionaires." -Abigail van Buren (a/k/a Dear Abby)